Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Explorative Phase II, Open Label Study of Afatinib in the Treatment of Advanced Cancer Carrying an EGFR, a HER2 or a HER3 Mutation

NCT03810872 is registered in ClinicalTrials.gov with Universitair Ziekenhuis Brussel as lead sponsor.

NCT NCT03810872
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03810872 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Explorative Phase II, Open Label Study of Afatinib in the Treatment of Advanced Cancer Carrying an EGFR, a HER2 or a HER3 Mutation
Lead sponsor
Universitair Ziekenhuis Brussel
Phase
Phase 2
Overall status
Unknown status
Start date
June 21, 2017
Completion date
December 31, 2022
Enrollment
87 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

cancers harbouring an egfr mutation, (excluding non-squamous non- small cell lung cancer, a registered indication), a her2 mutation or a her3 mutation